The Proteolytic Activity of Separase in BCR-ABL-Positive Cells Is Increased by ImatinibWiltrud Haaß(Heidelberg University), Wolfgang Seifarth(Heidelberg University)PLoS ONEAugust 3, 201210.1371/journal.pone.0042863Cited by 17SaveCiteExport RISWatch citationsRelated PapersAssessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants|Leukemia|2017|339Measurement of Separase Proteolytic Activity in Single Living Cells by a Fluorogenic Flow Cytometry Assay|PLoS ONE|2015|12